Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Bibliography

• MAGA G, SPADARI S: Combinations against combinations: associations of anti-HIV 1 reverse transcriptase drugs challenged by constellations of drug resistance mutations. Curr. Drug Metab. (2002) 3(1):73-95.
   PubMed Web of Science ®Google Scholar
• CAMPIANI G, RAMUNNO A, MAGA G et al.: Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm. Des (2002) 8(8):615-657.
   PubMed Web of Science ®Google Scholar
• ARNOLD E, DAS K, DING J et al.: Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des. Discov. (1996) 13(3-4):29-47.
   PubMedGoogle Scholar
• BALZARINI J: Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. (1999) 58(1):1-27.
   PubMed Web of Science ®Google Scholar
• DEEKS SG: International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl. 1):S25-S33.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: New anti-HIV agents and targets. Med. Res. Rev. (2002) 22(6):531-565.
   PubMed Web of Science ®Google Scholar
• CLOTET B: Efavirenz: resistance and cross-resistance. Int. J. Clin. Pract. Suppl. (1999) 103:21-25.
   PubMedGoogle Scholar
• CORBETT JW, KO SS, RODGERS JD et al.: Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. (2000) 43(10):2019-2030.
   PubMed Web of Science ®Google Scholar
• TURNER BG, SUMMERS MF: Structural biology of HIV. J. Mol. Biol. (1999) 285(1):1-32.
   PubMed Web of Science ®Google Scholar
• REN J, ESNOUF R, GARMAN E et al.: High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. (1995) 2:293-302.
   PubMedGoogle Scholar
• TEMIZ NA, BAHAR I: Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins (2002) 49(1):61-70.
   PubMed Web of Science ®Google Scholar
• SPENCE RA, KATI WM, ANDERSON KS, JOHNSON KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science (1995) 267:988-993.
   PubMed Web of Science ®Google Scholar
• SPENCE R, ANDERSON KS, JOHNSON KA: HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry (1996) 35:1054-1063.
   PubMed Web of Science ®Google Scholar
• TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. (1994) 243(3):369-387.
   PubMed Web of Science ®Google Scholar
• ERICKSON JW, BURT SK: Structural mechanisms of HIV drug resistance. Ann. Rev. Pharmacol. Toxicol. (1996) 36:545-571.
   PubMed Web of Science ®Google Scholar
• MAGA G, AMACKER M, RUEL N, HUBSCHER U, SPADARI S: Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. (1997) 274(5):738-747.
   PubMed Web of Science ®Google Scholar
• REN J, MILTON J, WEAVER KL et al.: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold. Des. (2000) 8(10):1089-1094.
   Google Scholar
• LINDBERG J, SIGURDSSON S, LOWGREN S et al.: Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. (2002) 269(6):1670-1677.
   PubMedGoogle Scholar
• PEDERSEN OS, PEDERSEN EB: Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antivir. Chem. Chemother. (1999) 10(6):285-314.
   PubMed Web of Science ®Google Scholar
• YOAKIM C, BONNEAU PR, DEZIEL R et al.: Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyrido- diazepinone derivatives. Bioorg. Med. Chem. Lett. (2004) 14(3):739-742.
   PubMed Web of Science ®Google Scholar
• BONNEAU PR, CYWIN CL, DEZIEL R et al.: Towards a second generation non-nucleoside reverse transcriptase inhibitors of HIV-1 with broad spectrum of activity. National Meeting of the American Chemical Society. New York, USA (2003).
   Google Scholar
• BONNEAU PR, DOYON L, DUAN J et al.: Second generation non-nucleoside reverse transcriptase inhibitors of HIV-1. 11th Conference on Retroviruses and Opportunistic Infection. San Francisco, USA (2004) Poster 530.
   Google Scholar
• O’MEARA JA, YOAKIM C, BONNEAU PR et al.: Novel 8-substituted dipyridodiazepinone inhibitors with a broad spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. (2005) 48(17):5580-5588.
   PubMed Web of Science ®Google Scholar
• PAUWELS R, ANDRIES K, DEBYSER Z et al.: Potent and highly selective human immunodeficiency virus Type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA (1993) 90(5):1711-1715.
   PubMed Web of Science ®Google Scholar
• GRUZDEV B, HORBAN A, BORON-KACZMARSKA A et al.: TMC120, a new non-nucleoside reverse transcriptase inhibitor, is a potent antiretroviral in treatment naive, HIV-1 infected subjects. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA (2001).
   Google Scholar
• SANKATSING S, WEVERLING G, VAN ‘T KLOOSTER G, PRINS J, LANGE J: TMC125 monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA (2002).
   Google Scholar
• JANSSEN PA, LEWI PJ, ARNOLD E et al.: In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E) -2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. (2005) 48(6):1901-1909.
   PubMed Web of Science ®Google Scholar
• GUILLEMONT J, PASQUIER E, PALANDJIAN P et al.: Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus Type 1. J. Med. Chem. (2005) 48(6):2072-2079.
   PubMed Web of Science ®Google Scholar
• HEERES J, DE JONGE MR, KOYMANS LM et al.: Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. J. Med. Chem. (2005) 48(6):1910-1918.
   PubMed Web of Science ®Google Scholar
• DE JONGE MR, KOYMANS LM, VINKERS HM et al.: Structure based activity prediction of HIV-1 reverse transcriptase inhibitors. J. Med. Chem. (2005) 48(6):2176-2183.
   PubMed Web of Science ®Google Scholar
• CHAN JH, FREEMAN GA, TIDWELL JH et al.: Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. (2004) 47(5):1175-1182.
   PubMed Web of Science ®Google Scholar
• HOPKINS AL, REN J, MILTON J et al.: Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1. J. Med. Chem. (2004) 47(24):5912-5922.
   PubMed Web of Science ®Google Scholar
• FREEMAN GA, ANDREWS III CW 3RD, HOPKINS AL et al.: Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. J. Med. Chem. (2004) 47(24):5923-5936.
   PubMed Web of Science ®Google Scholar
• CHIMIRRI A, GRASSO S, MOLICA C et al.: Anti-HIV agents. IV. Synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles. Farmaco (1996) 51(4):279-282.
   PubMedGoogle Scholar
• BARRECA ML, RAO A, DE LUCA L et al.: Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT. J. Med. Chem. (2005) 48(9):3433-3437.
   PubMed Web of Science ®Google Scholar
• ARTICO M, SILVESTRI R, STEFANCICH G et al.: Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Arch. Pharm. (1995) 328(3):223-229.
   PubMed Web of Science ®Google Scholar
• ARTICO M, SILVESTRI R, MASSA S et al.: 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the antihuman immunodeficiency virus Type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. (1996) 39(2):522-530.
   PubMed Web of Science ®Google Scholar
• SILVESTRI R, DE MARTINO G, LA REGINA G et al.: Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. (2003) 46(12):2482-2493.
   PubMed Web of Science ®Google Scholar
• SILVESTRI R, ARTICO M, DE MARTINO G et al.: Simple, short peptide derivatives of l-737,126 active in vitro against HIV-1 WT and variants carrying NNRTI resistance mutations. J. Med. Chem. (2004) 47(15):3892-3896.
   PubMed Web of Science ®Google Scholar
• CHAN JH, HONG JS, HUNTER RN et al.: 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. (2001) 44(12):1866-1882.
   PubMed Web of Science ®Google Scholar
• SILVESTRI R, ARTICO M: Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug-resistant mutants. Curr. Pharm. Des. (2005) 11(29):3779-3806.
   PubMed Web of Science ®Google Scholar
• LOKSHA YM, EL-BARBARY AA, EL-BADAWI MA et al.: Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues. Bioorg Med. Chem. (2005) 13(13):4209-4220.
   PubMed Web of Science ®Google Scholar
• RANISE A, SPALLAROSSA A, SCHENONE S et al.: Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives. J. Med. Chem. (2003) 46(5):768-781.
   PubMed Web of Science ®Google Scholar
• RANISE A, SPALLAROSSA A, CESARINI S et al.: Structure-based design, parallel synthesis, structure–activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. J. Med. Chem. (2005) 48(11):3858-3873.
   PubMed Web of Science ®Google Scholar
• BENJAHAD A, CROISY M, MONNERET C et al.: 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. J. Med. Chem. (2005) 48(6):1948-1964.
   PubMed Web of Science ®Google Scholar
• CANCIO R, SILVESTRI R, RAGNO R, et al.: High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus Type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme. Antimicrob. Agents. Chemother. (2005) 49(11):4546-4554
   PubMed Web of Science ®Google Scholar
• SANKATSING SU, WEVERLING GJ, PEETERS M et al.: TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. Aids (2003) 17(18):2623-2627.
   PubMed Web of Science ®Google Scholar
• GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYAE et al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. Aids (2003) 17(17):2487-2494.
   PubMed Web of Science ®Google Scholar